Clinical Classification and Prognosis of Patients with Multiple Sclerosis in Northern China

Abstract:

Objective: To study the clinical classification of multiple sclerosis (MS) by analyzing the features of the magnetic resonance imaging (MRI) on brain and spinal cord and surveying the natural history. Methods: MRI examination was conducted on 132 clinically diagnosed multiple sclerosis patients and their quality of life and disability rate were graded. Results: The general distribution of lesions in the nervous system was obtained. In northern China, relapsing-remitting MS (RRMS) by natural course classification and simple brain MS by lesion distribution classification lead to fewer neurological deficits with a relatively top life quality. Meanwhile, there is a tendency for the correlation between the pathogenetic locations of MS and its natural course prognosis. Conclusion: To improve the understanding of the prognosis of MS and promote the diagnosis ability to guide MS treatment. Multiple sclerosis (MS) is a common immune-mediated chronic disease of the central nervous system with the demyelination of white matter as the main pathological feature. The incidence of MS has a significant regional difference and studies on the natural history classification and lesions distribution classification of MS patients in northern China are not sufficient. In this study, natural history and lesions distribution of MS patients were classified by MRI approach and the impacts of each MS classification on neurological deficits and quality of life were observed. In this thesis, features and prognosis of MS classifications in northern China are discussed for the purpose of improving the level of diagnosis and treatment.

• Periodical: Advanced Materials Research (Volume 680)
• Pages: 606-610
• DOI: https://doi.org/10.4028/www.scientific.net/AMR.680.606
• Online since: April 2013
• Authors: Xue Mei Han, Ying Chang, Zhao Shi Zheng, Song Yan Liu
• Keywords: Expanded Disability Status Scale, Multiple Sclerosis, Multiple Sclerosis Quality of Life-54 Instrument, Primary-Progressive MS, Progressive-Relapsing MS, Relapsing-Remitting MS, Secondary-Progressive MS

References

[1] Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald Criteria,. Ann Neurol. 2005, 58(6): 840-846.

DOI: 10.1002/ana.20703

[2] Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996, 46(4): 907-911.

DOI: 10.1212/wnl.46.4.907

[3] Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983, 33(11): 1444-1452.

DOI: 10.1212/wnl.33.11.1444

[4] Bebo BF Jr, Schuster JC, Vandenbark AA, et al. Androgens alter the cytokine profile and reduce encephalitogenicity of myelin-reactive T cells. Journal of Immunology. 1999, 162: 35–40.

DOI: 10.4049/jimmunol.162.1.35

[5] Gold SM, Voskuhl RR. Estrogen and testosterone therapies in multiple sclerosis. Int Rev Psychiatry. 2010, 22(1): 2-13.

[6] Tomassini V, Onesti E, Mainero C, et al. Sex hormones modulate brain damage in multiple sclerosis: MRI evidence. J Neurol Neurosurg Psychiatry. 2005, 76(2): 272-275.

DOI: 10.1136/jnnp.2003.033324

[7] A. Czlonkowska, A. Ciesielska, G. Gromadzka I. Kurkowska-Jastrzebska. Estrogen and cytokines production - the possible cause of gender differences in neurological diseases. Current pharmaceutical design. 2005, 11(8): 1017-30.

DOI: 10.2174/1381612053381693

[8] Filippi M, Rocca MA, Barkhof F, et al. Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol. 2012, 11(4): 349-360.

[9] Zamboni P. The big idea: Iron-dependent inflammation in venous disease and proposed parallels in multiple sclerosis. J R Soc Med. 2006, 99: 589-593.

DOI: 10.1177/014107680609901122

[10] Haines JD, Inglese M, Casaccia P. Axonal Damage in Multiple Sclerosis. Mt Sinai J Med. 2011, 78(2): 231-243.

DOI: 10.1002/msj.20246

[11] Miller E. Multiple sclerosis. Adv Exp Med Biol. 2012, 724(0): 222-238.

[12] Horakova D, Kalincik T, Dusankova Blahova J, et al. Clinical correlates of grey matter pathology in multiple sclerosis. BMC Neurol. 2012: Mar 7; 12: 1.

DOI: 10.1186/1471-2377-12-10

[13] Gilmore CP, DeLuca GC, Bö L, et al. Spinal cord neuronal pathology in multiple sclerosis. Brain Pathol. 2009, 19(4): 642-649.

DOI: 10.1111/j.1750-3639.2008.00228.x